July 17, 2024CancersOpen Access

Reduced Dose of Post-Transplant Cyclophosphamide with Tacrolimus for the Prevention of Graft-versus-Host Disease in HLA-Matched Donor Peripheral Blood Stem Cell Transplants: A Prospective Pilot Study

View Full Paper

Ask AI

Bookmark

Reduced-dose post-transplant cyclophosphamide with tacrolimus achieved low rates of acute graft-versus-host disease, with no observed grade IV or steroid-refractory manifestations.
Grade II–IV acute graft-versus-host disease reached 18.2% at day 100, while two-year overall survival was 77.1% and one-year moderate-to-severe chronic disease was 6.4% across 22 patients.
Prospective pilot study of reduced cyclophosphamide (40 mg/kg/day) demonstrated prompt engraftment at 15 days, highlighting adequate immunosuppression with a favorable safety profile.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Prospective pilot study demonstrates reduced cyclophosphamide prevents graft-versus-host disease in HLA-matched stem cell transplant recipients, indicating robust efficacy with low toxicity.

Cite This Study

Juárez et al. (2024) studied this question.

synapsesocial.com/papers/68e5fef1b6db643587592e33 https://doi.org/10.3390/cancers16142567

View Full Paper

Ask AI

Bookmark

Implication

Prospective pilot study demonstrates reduced cyclophosphamide prevents graft-versus-host disease in HLA-matched stem cell transplant recipients, indicating robust efficacy with low toxicity.

Reduced Dose of Post-Transplant Cyclophosphamide with Tacrolimus for the Prevention of Graft-versus-Host Disease in HLA-Matched Donor Peripheral Blood Stem Cell Transplants: A Prospective Pilot Study

Key Points

Discussion

Implication

Cite This Study

Reduced Dose of Post-Transplant Cyclophosphamide with Tacrolimus for the Prevention of Graft-versus-Host Disease in HLA-Matched Donor Peripheral Blood Stem Cell Transplants: A Prospective Pilot Study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider